Table 4 Comparison of standardized rates of thrombosis in our study versus previous randomized controlled trials of warfarin in antiphospholipid syndrome
From: A single-arm feasibility cohort study of rivaroxaban in antiphospholipid syndrome
Our study | Crowther, 2003 | Finazzi, 2005 | Cohen, 2016 | Pengo, 2018 | |
|---|---|---|---|---|---|
No. of patients (No. with arterial events at baseline) | 82 (5) | 114 (27) | 109 (44) | 116 (0) | Warfarin arm: 61 (14) |
Length of follow-up | 19 months (mean) | 2.7 years (mean) | 3.6 years (median) | 6 months | 569 days (mean) |
No. of recurrent VTE events (%) | 2 (2.4) | 5 (4.4) | 3 (2.3) | 0 (0) | 0 (0) |
No. of recurrent arterial events (%) | 2 (2.4) | 3 (2.6) | 7 (6.4) | 0 (0) | 0 (0) |
Recurrent thrombotic events/100 patient-years | 3.1 | 2.6 | 2.5 | 0 | 0 |